EDIT
Price
$2.53
Change
-$0.07 (-2.69%)
Updated
Aug 6, 04:38 PM (EDT)
Capitalization
217.65M
96 days until earnings call
RXRX
Price
$5.49
Change
-$0.04 (-0.72%)
Updated
Aug 6, 04:59 PM (EDT)
Capitalization
2.4B
91 days until earnings call
Interact to see
Advertisement

EDIT vs RXRX

Header iconEDIT vs RXRX Comparison
Open Charts EDIT vs RXRXBanner chart's image
Editas Medicine
Price$2.53
Change-$0.07 (-2.69%)
Volume$1.87K
Capitalization217.65M
Recursion Pharmaceuticals
Price$5.49
Change-$0.04 (-0.72%)
Volume$119.83K
Capitalization2.4B
EDIT vs RXRX Comparison Chart in %
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. RXRX commentary
Aug 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 06, 2025
Stock price -- (EDIT: $2.60 vs. RXRX: $5.53)
Brand notoriety: EDIT and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 63% vs. RXRX: 112%
Market capitalization -- EDIT: $217.65M vs. RXRX: $2.4B
EDIT [@Biotechnology] is valued at $217.65M. RXRX’s [@Biotechnology] market capitalization is $2.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $215.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both EDIT and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than RXRX.

Price Growth

EDIT (@Biotechnology) experienced а +0.39% price change this week, while RXRX (@Biotechnology) price change was -7.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +14.77%, and the average quarterly price growth was +13.51%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 10, 2025.

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.4B) has a higher market cap than EDIT($218M). EDIT YTD gains are higher at: 104.724 vs. RXRX (-18.195). EDIT has higher annual earnings (EBITDA): -244.52M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. EDIT (221M). EDIT has less debt than RXRX: EDIT (31.1M) vs RXRX (92.9M). RXRX has higher revenues than EDIT: RXRX (59.8M) vs EDIT (35.8M).
EDITRXRXEDIT / RXRX
Capitalization218M2.4B9%
EBITDA-244.52M-524.77M47%
Gain YTD104.724-18.195-576%
P/E RatioN/AN/A-
Revenue35.8M59.8M60%
Total Cash221M500M44%
Total Debt31.1M92.9M33%
FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
72
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EDITRXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGOVX28.920.05
+0.17%
First Eagle Overseas A
IJPTX14.27N/A
N/A
VY® JPMorgan Emerging Markets Equity S2
IEOSX16.13N/A
N/A
Voya Large Cap Growth Port S
EIHSX13.11N/A
N/A
Eaton Vance Worldwide Health Sci I
VICCX22.14N/A
N/A
USA Mutuals Vice C